Company Filing History:
Years Active: 1989-1991
Title: Hisami Ikeda: Innovator in Cancer Research
Introduction
Hisami Ikeda is a prominent inventor based in Asahikawa, Japan, known for her significant contributions to cancer research. She has been instrumental in developing innovative solutions that aid in the detection and treatment of melanoma, a serious form of skin cancer. With a total of two patents to her name, Ikeda's work has made a notable impact in the field of oncology.
Latest Patents
Ikeda's latest patents include groundbreaking inventions related to monoclonal antibodies. The first patent focuses on monoclonal antibodies that recognize the gp130 antigen of human cells. This invention provides methods for detecting distinct determinants on this antigen through immunoassays. These monoclonal antibodies are particularly useful in identifying the gp130 antigen in human cells, including melanoma cells that express this antigen. The second patent involves monoclonal antibodies that specifically recognize human melanoma cells, detailing the method of production and potential applications in cancer treatment.
Career Highlights
Ikeda is affiliated with the Sloan-Kettering Institute for Cancer Research, where she continues to advance her research in cancer therapies. Her work has been pivotal in enhancing the understanding of melanoma and developing targeted treatments that can improve patient outcomes.
Collaborations
Ikeda has collaborated with esteemed colleagues, including Kenneth O. Lloyd and Anthony P. Albino, to further her research initiatives. These collaborations have fostered a productive environment for innovation and discovery in cancer research.
Conclusion
Hisami Ikeda's contributions to the field of cancer research through her innovative patents and collaborations highlight her dedication to improving cancer detection and treatment. Her work continues to inspire advancements in medical science and offers hope for better therapeutic options for melanoma patients.